Genetic contribution to C-reactive protein levels in severe obesity

Molecular Genetics and Metabolism

Volumn 105, Issue 3, 2012, Pages 494-501

  Faucher, Geneviève ^a,b,c   Guénard, Frédéric ^a,b,c   Bouchard, Luigi ^d   Garneau, Véronique ^a,b,c   Turcot, Valérie ^a,b,c   Houde, Alain ^a,b,c   Tchernof, André ^b,c   Bergeron, Jean ^b   Deshaies, Yves ^e   Hould, Frédéric Simon ^c   Lebel, Stéfane ^c   Marceau, Picard ^c   Vohl, Marie Claude ^a,b,c  

^a LAVAL UNIVERSITY   (Canada)

^b Université Laval   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d CHICOUTIMI HOSPITAL   (Canada)

^e LAVAL UNIVERSITY   (Canada)

Author keywords

CD163; CXCL9; IFI30; Inflammation; Obesity; TSLP

Indexed keywords

C REACTIVE PROTEIN; CD163 ANTIGEN; CXCL9 CHEMOKINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERFERON GAMMA INDUCIBLE PROTEIN 30; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN; THYMIC STROMAL LYMPHOPOIETIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; DNA POLYMORPHISM; EXON; FEMALE; GENE FREQUENCY; GENE LOCATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CHEMOKINE CXCL9; CYTOKINES; FEMALE; GENOTYPE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OBESITY, MORBID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDOREDUCTASES ACTING ON SULFUR GROUP DONORS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CELL SURFACE; SEQUENCE ANALYSIS, DNA;

EID: 84858291433     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.11.198     Document Type: Article

References (63)

1. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
2. Koenig W., Sund M., Frohlich M., Fischer H.G., Lowel H., Doring A., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men - results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999, 99:237-242.
3. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 2002, 347:1557-1565.
4. Haffner S.M. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am. J. Cardiol. 2006, 97:3A-11A.
5. Ackermann D., Jones J., Barona J., Calle M.C., Kim J.E., LaPia B., et al. Waist circumference is positively correlated with markers of inflammation and negatively with adiponectin in women with metabolic syndrome. Nutr. Res. 2011, 31:197-204.
6. Blaha M.J., Rivera J.J., Budoff M.J., Blankstein R., Agatston A., O'Leary D.H., et al. Association between obesity, high-sensitivity C-reactive protein ≥2mg/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2011, 31:1430-1438.
7. Faintuch J., Marques P.C., Bortolotto L.A., Faintuch J.J., Cecconello I. Systemic inflammation and cardiovascular risk factors: are morbidly obese subjects different?. Obes. Surg. 2008, 18:854-862.
8. Karelis A.D., St Pierre D.H., Conus F., Rabasa-Lhoret R., Poehlman E.T. Metabolic and body composition factors in subgroups of obesity: what do we know?. J. Clin. Endocrinol. Metab. 2004, 89:2569-2575.
9. Farooqi I.S., O'Rahilly S. Genetic factors in human obesity. Obes. Rev. 2007, 8(Suppl 1):37-40.
10. Bouchard L., Tchernof A., Deshaies Y., Marceau S., Lescelleur O., Biron S., et al. ZFP36: a promising candidate gene for obesity-related metabolic complications identified by converging genomics. Obes. Surg. 2007, 17:372-382.
11. Luster A.D., Weinshank R.L., Feinman R., Ravetch J.V. Molecular and biochemical characterization of a novel gamma-interferon-inducible protein. J. Biol. Chem. 1988, 263:12036-12043.
12. Phan U.T., Lackman R.L., Cresswell P. Role of the C-terminal propeptide in the activity and maturation of gamma-interferon-inducible lysosomal thiol reductase (GILT). Proc. Natl. Acad. Sci. U. S. A. 2002, 99:12298-12303.
13. Lackman R.L., Cresswell P. Exposure of the promonocytic cell line THP-1 to Escherichia coli induces IFN-gamma-inducible lysosomal thiol reductase expression by inflammatory cytokines. J. Immunol. 2006, 177:4833-4840.
14. O'Donnell P.W., Haque A., Klemsz M.J., Kaplan M.H., Blum J.S. Cutting edge: induction of the antigen-processing enzyme IFN-gamma-inducible lysosomal thiol reductase in melanoma cells Is STAT1-dependent but CIITA-independent. J. Immunol. 2004, 173:731-735.
15. Law S.K., Micklem K.J., Shaw J.M., Zhang X.P., Dong Y., Willis A.C., et al. A new macrophage differentiation antigen which is a member of the scavenger receptor superfamily. Eur. J. Immunol. 1993, 23:2320-2325.
16. Moestrup S.K., Moller H.J. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann. Med. 2004, 36:347-354.
17. Farber J.M. HuMig: a new human member of the chemokine family of cytokines. Biochem. Biophys. Res. Commun. 1993, 192:223-230.
18. Viola A., Luster A.D. Chemokines and their receptors: drug targets in immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 2008, 48:171-197.
19. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 2006, 354:610-621.
20. Tensen C.P., Flier J., Rampersad S.S., Sampat-Sardjoepersad S., Scheper R.J., Boorsma D.M., et al. Genomic organization, sequence and transcriptional regulation of the human CXCL 11(1) gene. Biochim. Biophys. Acta 1999, 1446:167-172.
21. Sims J.E., Williams D.E., Morrissey P.J., Garka K., Foxworthe D., Price V., et al. Molecular cloning and biological characterization of a novel murine lymphoid growth factor. J. Exp. Med. 2000, 192:671-680.
22. Friend S.L., Hosier S., Nelson A., Foxworthe D., Williams D.E., Farr A. A thymic stromal cell line supports in vitro development of surface IgM+ B cells and produces a novel growth factor affecting B and T lineage cells. Exp. Hematol. 1994, 22:321-328.
23. He R., Geha R.S. Thymic stromal lymphopoietin. Ann. N. Y. Acad. Sci. 2010, 1183:13-24.
24. Ziegler S.F., Artis D. Sensing the outside world: TSLP regulates barrier immunity. Nat. Immunol. 2010, 11:289-293.
25. Marceau P., Hould F.S., Simard S., Lebel S., Bourque R.A., Potvin M., et al. Biliopancreatic diversion with duodenal switch. World J. Surg. 1998, 22:947-954.
26. Vohl M.C., Sladek R., Robitaille J., Gurd S., Marceau P., Richard D., et al. A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. Obes. Res. 2004, 12:1217-1222.
27. Ledue T.B., Weiner D.L., Sipe J.D., Poulin S.E., Collins M.F., Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann. Clin. Biochem. 1998, 35(Pt 6):745-753.
28. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
29. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
30. de Bakker P.I., Yelensky R., Pe'er I., Gabriel S.B., Daly M.J., Altshuler D. Efficiency and power in genetic association studies. Nat. Genet. 2005, 37:1217-1223.
31. Aronson D., Bartha P., Zinder O., Kerner A., Markiewicz W., Avizohar O., et al. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int. J. Obes. Relat. Metab. Disord. 2004, 28:674-679.
32. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-369.
33. Lemieux I., Pascot A., Prud'homme D., Almeras N., Bogaty P., Nadeau A., et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler. Thromb. Vasc. Biol. 2001, 21:961-967.
34. Fontana L., Eagon J.C., Trujillo M.E., Scherer P.E., Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56:1010-1013.
35. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003, 112:1796-1808.
36. Turcot V., Bouchard L., Faucher G., Tchernof A., Deshaies Y., Perusse L., et al. A polymorphism of the interferon-gamma-inducible protein 30 gene is associated with hyperglycemia in severely obese individuals. Hum. Genet. 2011, [Electronic publication ahead of print].
37. Curocichin G., Wu Y., McDade T.W., Kuzawa C.W., Borja J.B., Qin L., et al. Single-nucleotide polymorphisms at five loci are associated with C-reactive protein levels in a cohort of Filipino young adults. J. Hum. Genet. 2011, [Electronic publication ahead of print].
38. Enquobahrie D.A., Rice K., Williams O.D., Williams M.A., Gross M.D., Lewis C.E., et al. IL1B genetic variation and plasma C-reactive protein level among young adults: the CARDIA study. Atherosclerosis 2009, 202:513-520.
39. Cuda C., Badawi A., Karmali M., El-Sohemy A. Polymorphisms in Toll-like receptor 4 are associated with factors of the metabolic syndrome and modify the association between dietary saturated fat and fasting high-density lipoprotein cholesterol. Metabolism 2011, 60:1131-1135.
40. Satoh J., Obayashi S., Misawa T., Tabunoki H., Yamamura T., Arima K., et al. Neuromyelitis optica/Devic's disease: gene expression profiling of brain lesions. Neuropathology 2008, 28:561-576.
41. Trynka G., Zhernakova A., Romanos J., Franke L., Hunt K.A., Turner G., et al. Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling. Gut 2009, 58:1078-1083.
42. Barjaktarevic I., Rahman A., Radoja S., Bogunovic B., Vollmer A., Vukmanovic S., et al. Inhibitory role of IFN-gamma-inducible lysosomal thiol reductase in T cell activation. J. Immunol. 2006, 177:4369-4375.
43. Lackman R.L., Cresswell P. Exposure of the promonocytic cell line THP-1 to Escherichia coli induces IFN-gamma-inducible lysosomal thiol reductase expression by inflammatory cytokines. J. Immunol. 2006, 177:4833-4840.
44. Arunachalam B., Phan U.T., Geuze H.J., Cresswell P. Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT). Proc. Natl. Acad. Sci. U. S. A. 2000, 97:745-750.
45. Kushner I., Rzewnicki D., Samols D. What does minor elevation of C-reactive protein signify?. Am. J. Med. 2006, 119. 166.e17-28.
46. Ridker P.M., Hennekens C.H., Rifai N., Buring J.E., Manson J.E. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999, 100:713-716.
47. Laberge A.M. Prevalence and distribution of genetic diseases in Quebec: impact of the past on the present. Med. Sci. (Paris) 2007, 23:997-1001.
48. Laberge A.M., Michaud J., Richter A., Lemyre E., Lambert M., Brais B., et al. Population history and its impact on medical genetics in Quebec. Clin. Genet. 2005, 68:287-301.
49. Singh T., Newman A.B. Inflammatory markers in population studies of aging. Ageing Res. Rev. 2011, 10:319-329.
50. Wannamethee S.G., Lowe G.D., Shaper A.G., Rumley A., Lennon L., Whincup P.H. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur. Heart J. 2005, 26:1765-1773.
51. Pischon T., Boeing H., Hoffmann K., Bergmann M., Schulze M.B., Overvad K., et al. General and abdominal adiposity and risk of death in Europe. N. Engl. J. Med. 2008, 359:2105-2120.
52. Elliott P., Chambers J.C., Zhang W., Clarke R., Hopewell J.C., Peden J.F., et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009, 302:37-48.
53. Ridker P.M., Pare G., Parker A., Zee R.Y., Danik J.S., Buring J.E., et al. Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am. J. Hum. Genet. 2008, 82:1185-1192.
54. Kaptoge S., Di A.E., Lowe G., Pepys M.B., Thompson S.G., Collins R., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140.
55. Rana J.S., Arsenault B.J., Despres J.P., Cote M., Talmud P.J., Ninio E., et al. Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. Eur. Heart J. 2011, 32:336-344.
56. Danesh J., Pepys M.B. C-reactive protein and coronary disease: is there a causal link?. Circulation 2009, 120:2036-2039.
57. Shah T., Casas J.P., Cooper J.A., Tzoulaki I., Sofat R., McCormack V., et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int. J. Epidemiol. 2009, 38:217-231.
58. Miura T. C-reactive protein (CRP) is not a mere marker, but an active pathogenic substance. Circ. J. 2011, 75:1579-1580.
59. Mora S., Ridker P.M. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention?. Am. J. Cardiol. 2006, 97:33A-41A.
60. Zacho J., Tybjaerg-Hansen A., Jensen J.S., Grande P., Sillesen H., Nordestgaard B.G. Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med. 2008, 359:1897-1908.
61. Devaraj S., Singh U., Jialal I. Human C-reactive protein and the metabolic syndrome. Curr. Opin. Lipidol. 2009, 20:182-189.
62. Ridker P.M., Wilson P.W., Grundy S.M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation 2004, 109:2818-2825.
63. Tzotzas T., Evangelou P., Kiortsis D.N. Obesity, weight loss and conditional cardiovascular risk factors. Obes. Rev. 2011, 12:e282-e289.